As the pharmaceutical and biotech industries increasingly shift attention to biologics, much more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For the large GPCR and ion channel target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs and the potential for using antibodies for the targeted delivery of therapeutics. The PEGS Europe Membrane Protein track provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow biologic drugs for these target families to advance into the clinic and beyond.